Neutonic Raises $6m at $60m Valuation to Accelerate Global Expansion Across Retail and New Markets April 28, 2026 Investment backed by Alan Barrett, founder of Grenade, alongside a group of strategic investors, supporting the next phase of international growth
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status April 27, 2026 Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion
Cloudsmith Raises $72M Series C Led by TCV with Participation from Insight Partners to Control and Secure the AI-Powered Software Supply Chain April 23, 2026 Existing investors TCV and Insight Partners double down as Cloudsmith replaces legacy artifact management incumbents and builds the platform for the era of AI-driven software development
Synera Raises $40M Series B to Scale Agentic AI Engineering for Global Manufacturers April 14, 2026 Agentic AI platform that orchestrates the full engineering value chain across 80+ hardware engineering tools, which operates securely, on‑premise, and without disrupting existing systems, announces $40M (€35M) raise in Series B. Round led by Revaia, a leading European growth technology investor, with participation from UVC (€6M), to accelerate U.S. and international expansion. Adopted by NASA, BMW, Airbus, Volvo Trucks, and Hyundai to drive AI-ready organizational transformation, address the engineering talent shortage, and reduce costs and material usage.
Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology April 14, 2026 Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and largely unmet needs, Jeito will leverage its expertise to accelerate Adcendo’s broad, high-potential portfolio of novel therapies and deliver transformational benefits to patients
Clean Food Group: £4.5 Million Investment Led by Clean Growth Fund and New Agrarian April 14, 2026 Funding to accelerate scale-up of world-leading Knowsley fermentation facility
AS Invest Capital Ltd Group Launches €50 Million Bond Offering with 8.5% Yield April 9, 2026 AS Group, Hagenstraße 67, 14193 Berlin, Germany, is continuing to advance its capital markets–oriented growth strategy and is initiating a new corporate bond with a target volume of €50 million. The structuring of the issuance is being carried out via its subsidiary, AS Invest Capital LTD, London. With this planned issuance, the AS Group once [...]
UK Investors Back Narwhal Labs With £20 Million Investment to Launch DeepBlue Enterprise-Grade Agentic AI April 8, 2026 - Purpose-built for regulated enterprise and government use, DeepBlue OS turns missed customer leads into revenue, deployable in minutes with no setup cost
Netley Capital Secures Further Commitments for Tertiaries Franchise, Amid Strong Deal Flow April 8, 2026 Netley Capital (“Netley”), a private investment firm dedicated to tertiary investing, has secured further committed capital for its tertiaries franchise, validating strong institutional interest in the strategy. Since launching in September 2025 with $315 million in committed, deployable capital, the firm has continued to attract the backing of blue-chip institutional investors and leading family offices. [...]
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients April 8, 2026 This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creation In five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investors Jeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patients This fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions